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Abstract
Background: Current outcome predictors based on “molecular profiling” rely on gene lists
selected without consideration for their molecular mechanisms. This study was designed to
demonstrate that we could learn about genes related to a specific mechanism and further use this
knowledge to predict outcome in patients – a paradigm shift towards accurate “mechanism-
anchored profiling”. We propose a novel algorithm, PGnet, which predicts a tripartite mechanism-
anchored network associated to epigenetic regulation consisting of phenotypes, genes and
mechanisms. Genes termed as GEMs in this network meet all of the following criteria: (i) they are
c o - e x p r e s s e dw i t hg e n e sk n o w nt ob ei n v o l v e di nt h eb i o l o g i c a lm e c h a n i s mo fi n t e r e s t ,( i i )t h e ya r e
also differentially expressed between distinct phenotypes relevant to the study, and (iii) as a
biomodule, genes correlate with both the mechanism and the phenotype.
Results: This proof-of-concept study, which focuses on epigenetic mechanisms, was conducted in
a well-studied set of 132 acute lymphoblastic leukemia (ALL) microarrays annotated with nine
distinct phenotypes and three measures of response to therapy. We used established parametric
and non parametric statistics to derive the PGnet tripartite network that consisted of 10
phenotypes and 33 significant clusters of GEMs comprising 535 distinct genes. The significance of
PGnet was estimated from empirical p-values, and a robust subnetwork derived from ALL outcome
data was produced by repeated random sampling. The evaluation of derived robust network to
predict outcome (relapse of ALL) was significant (p = 3%), using one hundred three-fold cross-
validations and the shrunken centroids classifier.
Conclusion: To our knowledge, this is the first method predicting co-expression networks of
genes associated with epigenetic mechanisms and to demonstrate its inherent capability to predict
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Open Accesstherapeutic outcome. This PGnet approach can be applied to any regulatory mechanisms including
transcriptional or microRNA regulation in order to derive predictive molecular profiles that are
mechanistically anchored. The implementation of PGnet in R is freely available at http://Lussierlab.
org/publication/PGnet.
Background
By design, predictors of outcome based on gene
expression profiles are based on gene lists that do not
require knowledge of biological processes or molecular
mechanisms [1]. Though expression arrays have been
widely studied to improve prediction of clinical outcome
and to aid the decision of treatment strategy for cancer,
the resulting long list of genes lacking mechanistic
background is thus difficult to interpret to infer their
biological or clinical implications. Additionally, a poor
outcome may be caused by a diversity of molecular
disorders, for which the individual contribution may
vary in different patients suffering from the same cancer
[2]. In some cases, profiles are accompanied with follow-
on enrichment studies or curated annotations that
predict their possible mechanisms; while in other cases,
functional clustering has been proposed to understand
microarray data profiles [3]. In this manuscript, we
propose a novel computational strategy based on genes
associated to known biological mechanisms to derive
mechanism-anchored expression profiles ab initio that
can accurately predict disease outcome.
We hypothesized that those co-expression modules,
which are predictive of outcome, can be computationally
derived from genes known to regulate or to be regulated
by epigenetic mechanisms in previous studies and from
novel microarray expression specifically designed for a new
phenotypeforwhichtheepigeneticmechanismsmaynotbe
well understood [4,5]. Nearly every cancer consists of
genetic mutations of the transformed cells as well as
epigenetic abnormalities of non-mutational changes to
DNA that lead to alterations in gene expression [6]. While
geneticabnormalitiesfoundincancertypicallyaffectcancer-
promoting oncogenes and tumor suppressor genes, the
epigenetic regulation of molecular functions involves
reversible interactions which can affect gene expression
such as (i) DNA methylation [7], (ii) histone modification
[8], (iii) RNA transcription and the resulting proteins [9,10]
or miRNAs [11], that influence chromatin structure. For
example, histone deacetylation and the methylation of the
promoterregioncanaffect bindingoftranscriptionalfactors
to these DNA regions and result in transcriptional silencing
partly due to chromatin remodeling [12]. Indeed, combina-
tion therapy with inhibitors of DNA methyltransferase and
histone deacetylase is under investigation in cancer [13-15].
Additionally, epigenetic events occur in the coordinated
behavior of epigenetic proteins that regulate gene expres-
sions[15].Todemonstratetheapplicabilityoftheproposed
phenotype-genotype-network” method (PGnet), a set of
known biological mechanism-anchored genes are required
as the “seed” (input). Although this method can be
generalized to other molecular mechanisms and other
diseases, we focused this study on epigenetic alterations in
acute lymphoblastic leukemia (ALL).
To compute co-expression modules of genes in disease and
to infer their interplay generally require the integration of
data from a wide variety of sources [16,17]. For example,
some computational methods have been developed to
indentify shared regulatory inputs, functional pathways
and genetic interactions [2,18-21]. We have also previously
shown that co-expression patterns of genes found in
expression arrays designed around specific phenotypes
can be recapitulated in gene-phenotype relationships
derived from database/literature mining [22]. Further,
genome-scale reverse engineering of regulatory mechan-
isms in expression arrays have been developed and
successfully applied in mammalian cells [23]. For example,
A method called ARACNE has been shown to be effective
in practice by using a mutual information theoretic
approach which focuses on direct co-expression of genes
[24,25]. However, unsupervised combinations of every
molecular element that may interact via one or more
intermediaries can lead to a problem of multiplicity due to
the escalating number of comparisons and thus to a loss of
statistical power. Another method, FunNet, addresses
multiplicity by combining gene expression data with
Gene Ontology [26,27] or KEGG [28] annotations and
further performs transcriptional functional analysis over
co-expression [29]. Another method, StAM, identifies
expression signature by focusing on biological processes
which can characterize subgroup of patients [2]. However,
these methods are not designed to compute regulatory
networks that would also be differentially expressed in
multiple phenotypic contexts as well as co-expressed in
each individual. Our approach differs from these previous
methods in that genes are integrated to the profile
signature if: i) they are associated ab initio to the biological
mechanism of interest (here epigenetics), and ii) they are
derived from the a non-parametric statistic taking into
account comprehensive expression patterns of the every
gene in the microarray rather than from a subset of the
differential-expressed ones.
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ments from microarray data together with robust feature
selection technology [1], we are more likely to construct
meaningful, epigenetic mechanism-anchored, co-expres-
sion networks that are predictive of leukemia outcome.
To this end, we propose a novel supervised non-
parametric algorithm (PGnet) that builds a tripartite
network derived from (i) microarray expression profiles,
and (ii) prior knowledge about biological mechanisms.
PGnet is designed to identify sets of mechanism-
anchored genes that are both consistently co-expressed
across arrays and differentially expressed between
phenotypic conditions.
Methods
Arrays and phenotypes
We selected a large array dataset published by the
Downing research group (ALL arrays) [30] that com-
prises well characterized subtypes of ALL and other
clinical phenotypes, including cytogenetic characteristics,
molecular status and patient outcomes. The details for
leukemia phenotypes and sample size are provided in
Suppl. Methods (Additional file 1).
Epigenetic Seed Genes – ESGs (Suppl. Methods
(Additional file 1) and Suppl. Table 1 (Additional file 2))
Gene Ontology terms and PubMed were used to identify
genes with epigenetic effects. Genes were subsequently
mapped to Affymetrix probe-sets and curated into eight
categories.
Array analyses
The 132 ALL arrays were normalized with the variance
stabilization and calibration normalization (vsn)
method [31] using Bioconductor [32,33] package comp-
diagTools [34]. We then applied an additional inter
quartile range (IQR) filter [35] to eliminate genes lacking
sufficient variation across samples in expression (Suppl.
Methods (Additional file 1)).
Building a phenotype – gene network (PGnet)
The construction of a network comprising “Leukemia
Phenotypes” (LPs), “epigenetic seed Genes” (ESGs) and
co-expressed genes required six steps (see Figure 1 and
Suppl. Methods (Additional file 1) for details on steps
and equations).
Step 1a: Vector of genes co-expressed with the mechanism
seed genes
All genes that co-expressed with ESGs were sorted in a
vector based on the Pearson correlation coefficient
(PCC). Results were denoted as Vi ESGi, , ,... =12 4 8.
Step 1b: Vector of differentially expressed genes in ALL
At the same time, all genes were also sorted based on
their adjusted Student t-test conducted between the
phenotype of interest against the remaining pooled
phenotypes. Results were denoted as Vj LPj, , ,... =12 1 2.
Bioconductor [32,33] package stats w a su s e dt oc a l c u l a t e
the PCC and the package Twilight [36] was used to
calculate the adjusted t-score parameter.
Step 2
To compare two ordered lists of gene expressions, we
used OrderedList [37-39] from Bioconductor [32,33], a
Figure 1
Design of PGnet methods. Two sets of data are required
to construct the network: (i) VESG lists are produced by
analyzing the known epigenetic "seed genes" using the
pairwise standard Pearson correlation coefficient of the vsn
normalized gene expression levels between ESG and all
genes gn that meet the IQR filter criteria across all samples
where genes gn (n = 1,..., N), (ii) VLP lists are derived by
analyzing the gene's differential expression in each phenotype
of interest and evaluating its significance with an adjusted t-
test. The rows in both VESG and VLP lists represent every
genes in the microarray that meet the IQR filters, whereas
the columns are either epigenetic seed genes in the VESG lists
or phenotypes in the VLP lists.W et h e nu s et h eP G n e t
methodology to develop a similarity vector between the
epigenetic seed gene and a phenotype. We calculated the
vectorial similarity between each pair of ordered expression
of gene lists using a previously algorithm that we published,
orderedlist (Suppl. Methods (Additional file 1)) [37]. The
result is a ranked list of genes that are significantly associated
b a s e do nt h e i rr e s p e c t i v eVESGi and VLPj. We build a gene-
phenotype network where relationships are similarity scores
(Fig. 2). Legend: g: gene with microarray expression; ESG:
epigenetic seed gene; LP: leukemia phenotype.
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that we previously published, and has been shown more
sensitive to detect significant departure from a predicted
distribution than semi-quantitative enrichment approaches
such as the Fisher’s Exact Test or the the Chi-square test.
We calculated a matrix of similarity scores Ms =( si, j),
where each score si, j assessed the pair-wise similarities
between two vectors. The fist vector is the ordered co-
expression coefficients VESGi and the second one is the
ordered differential expression statistics VLPj. The similarity
score gives higher weights to ranking extremes: the top and
bottom ranks in both lists. In our method, we compared
the ranking of genes in the co-expression set with those
gene ranks from the phenotypic set. This resulted in a total
of two comparisons for each phenotype/“seed gene”
combination (correlation and anti-correlation).
Step 3: Vectorial Enrichment Optimization (VEO)
To evaluate the statistical significance of the similarity
score, we generated 2,000 controls through the permuta-
tion of each list of gene ranks and calculated empirical
p-values based on random scores. Two networks were
generated. In this proof-of-concept study, the arbitrary
but uniform significance threshold (T = 200, Suppl.
Methods (Additional file 1)) of included ranks was
chosen to define a set of GEMs with higher differential
expression in VEO that would yield a small network
(Suppl. Table 2 (Additional file 3) and Figure 2), where
the co-expressed with known “epigenetic seed genes”
and phenotype-specific genes are the genes within the
top 200 or bottom 200 in either of the two lists. An
optimal length for these ordered gene lists can also be
determined by unbiased optimization methods and
can generate a larger network (Suppl. Table 3 (Addi-
tional file 4)), however for the purpose of simplicity of
presentation – w ek e p tt h el i s ta tT=2 0 0f o rt h em a i n
figures, which is within the range of length considered
biologically significant in our unbiased and more
comprehensive studies (Suppl. Table 3 (Additional file
4)). In both the arbitrary threshold (T = 200) and the
optimal threshold cases, the significance of PGnet were
estimated by an empirical p-value of similarity scores by
permutation the ranks (number of permutations = 1000,
Suppl. Methods). And the adjustment threshold of
significance for vectorial similarity was conducted by
controlling the false discovery rates (q-value = 0.02)
[40,41] (Suppl. Methods (Additional file 1)).
Step 4
For each significant seed gene/phenotype pair we
considered these to be “linked.” By aggregating these
seed gene/phenotype pairs, we developed a tripartite
network PGnet.
Step 5: Visualization of the Tripartite Network
Meaning of shapes and colors in the network: triangle
(epigenetic seed genes), circle (predicted GEMs) and box
(phenotypes); red (up-regulated), blue (down-regulated)
and grey for vertex of a gene had more than one linkage
and was up-regulated in one condition but down-
regulated in a different condition (Suppl. Methods
(Additional file 1)). By color-coding the edges of the
graph, we are providing a direction to each similarity
vector, magenta line for correlation whereas turquoise
for anti-correlation. With these vectors, one can judge
how these genes express in a specific condition.
Step 6: Biological meaning of the network
Using Gene ontology, we conducted an enrichment of
the molecular function and biological processes among
the genes identified in the PGnet biomodules in order to
characterize biologically the network and we also
reviewed the literature for the genes involved in the
biomodules associated to BCR-ABL, T-ALL and hyperdi-
ploidy. Thus the resulting set of genes termed as Genes
significantly Expressed with the Mechanism (GEMs) in
the epigenetic context of this network meet all of the
following criteria: (i) they are co-expressed with genes
known to be involved in the biological mechanism of
interest, (ii) they are also differentially expressed
between distinct phenotypes relevant to the study, and
(iii) as a biomodule, genes correlate with both the
mechanism and the phenotype.
Robust predictive network and evaluation
The predictive capabilities of the derived network were
evaluated with two approaches: (a) quantitative compu-
tational studies of the accuracy of the predictor of
outcome, and (b) qualitative comparison of the PGnet
method to that of another reverse engineering one.
(a)Todemonstratetheaccuracyofthederivednetworkto
predict relapse, we performed a conservative evaluation
consisting of one hundred three-fold cross-validation
(CV) studies of the PGnet method. In other words, as
showninFigure 2c, the networkwas derived from 2/3 of
the randomly selected patients and the evaluation was
conductedontheremainingthird.Therandomselection
was conducted to conserve the respective group sizes
(normal, cancer) and was considered a more adequate
andseverecontrol[42].Thisprocedurewasrepeatedone
hundred times on different random resamplings. Two
different predictive methods were used as well: (i)
Prediction Analysis for Microarrays Class Prediction
[43] (PAM) that does not involve any machine learning
and (ii) the Support Vector Machine [44] (SVM) (Suppl.
Methods(Additionalfile1)andSuppl.Fig.2(Additional
file 5)). The resulting receiver operating characteristic
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Network modelling of epigenetic genes – phenotypes in ALL derived from PGnet. The complete tripartite network
produced by PGNet is available as Suppl. Fig. 1 (Additional file 14) and Suppl. Table 2 (Additional file 3). Here, panel (a) shows a
bipartite subset of 33 statistically significant associations linking 23 distinct epigenetic seed genes (ESGs, yellow triangle) to 10
distinct leukemia phenotypes (yellow squares). Distinct background colors of ESG gene names indicate distinct molecular
functionorbiologicalprocessrelatedtoortargetedbyepigeneticregulation(Suppl.Table1(Additionalfile2)).TwoLPsandone
ESG with asterisk were selected to show the details of a biomodule derived by PGnet (Figure 4). Red genes are those for which
the expression is up-regulated in the associated ALL phenotype, while blue ones are with down-regulated expression, and grey
ones are related to more than one phenotype with alternate up-down regulations (details of the full network in Suppl. Table 2
(Additional file 3)). Panel (b) shows a tripartite network that includes GEMs (grey circles) and focuses on the circled subset of
Panel a: the "ALL relapse". Panel (c) is a robust sub-network associated to ALL outcome (relapse vs. continuous complete
remission (CCR)). Three ESGs and 53 GEMs were obtained by 100 repetitions of 3-fold cross-validation of PGnet operating on
the subset of ALL arrays comprising 87 patients experiencing either "CCR" or "relapse" (n > 32, details in Suppl. Methods
(Additionalfile1)).NotethatALLsubtypesassociatedPGnetinpanela)andb)werederivedfromall132patients(inthiscasethe
biomodules of the sub-network 2b pertain to patients with relapse and not everything else). The robust sub-network in panel c)
was conducted for training a predictor of outcome. Only 87 out of the 132 samples contained outcome information related to
ALL relapse ("relapse" or "CCR" of ALL). Please note that some patients did have an outcome of secondary AML, a distinct form
of leukemia, and were excluded from panel 2c because this disease occurs at a later stage and the authors of the dataset did not
disclose the outcome of ALL for these patients. Thus the biomodules of Figure 2c overlap partially with those of Figure 2b.
BMC Bioinformatics 2009, 10(Suppl 9):S6 http://www.biomedcentral.com/1471-2105/10/S9/S6
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sponding p-values were calculated by the Bioconductor
[32,33] package verification [45]. A robust molecular
signature is one that repeatedly appears by random
sampling [1]. We further identified the GEMs correlated
with the ESGs that were identified as robust [1]. The
robustESGsrefertothoseGEMsthatwereamongthetop
5% frequencies in the one hundred iterations of the 3-
fold cross-validation (Figure B in Suppl. Methods
(Additional file 1)). Figure 3 illustrates the sub-network
associatedto the comparison between “Relapse” and the
“continuous complete remission – CCR” phenotypes.
(b) Finally we compared our results to those obtained by a
straightforward reverse engineering method (ARACNE).
Results
Seventy-one distinct epigenetic seed genes were identi-
fied in the literature review and denoted as “seed gene”
candidates for input in PGnet (Suppl. Table 1 (Addi-
tional file 2)). In the 132 ALL arrays, 7,256 out of 12,997
unique genes and 48 out of the 71 subset of ESGs satisfy
the IQR filter (bolded genes in Suppl. Table 1 (Addi-
tional file 2)). The 48 ESGs are thus enriched ab initio
among genes differentially expressed in ALL samples
suggesting a biological relevance in ALL (p = 5%, Fisher’s
Exact Test).
We built a gene-phenotype network specific for epige-
netic genes clusters in ALL as shown in Figures 2a and 2b.
The derived network comprises 33 significant nodes,
including eight clinical subtypes of ALL and two
outcome conditions (LP, vertex in yellow box), 23
epigenetic seed genes (ESG, yellow triangle) and 535
genes that co-express with ESGs (GEM, grey circle). Three
of these ESGs and 299 GEMs are up-regulated in
association to their phenotype(s) as compared with
their expression associated to the remaining pooled
phenotypes, while 14 ESGs and 203 GEMs are down-
regulated. In addition, 6 ESGs and 33 GEMs were up-
regulated in one phenotype but down-regulated in a
different phenotype, which are phenotype specifically
differential expressions (see Step 3 of Methods). A
summary of predictions is provided in Suppl. Table 2
(Additional file 3). These 23 ESGs genes are highly co-
expressed with epigenetic genes and also highly differ-
entially expressed in distinct ALL phenotypes groups
(CBX1, CBX5, CBX6, CBX7, PHLDA2, BAZ2A, BAZ2B,
MYST2, MYST4, MECP2, SMARCA2, HDAC4, HDAC5,
HDAC6, HDAC7A, HDAC9, SMARCA4, SMYD3,
SUV39H1, DNMT3A, DNMT3B, PRDM2 and MBD2).
To validate the prognostic ability of the genes in PGnet
associated with leukemia relapse, we performed one
hundred three-fold cross-validations in two ways (Suppl.
Methods (Additional file 1) and Suppl. Fig. 2 (Additional
file 5)). Using the PAM classification that does not require
machine-learning, the predictions were accurate (AUC =
0.65, p = 3%, Suppl. Fig. 3 (Additional file 6)). We also
conducted a severe control by randomly selecting genes
differentially expressed in the array and the p-values of the
derived predictors ranged from 12% to 67%, further
corroborating that the epigenetic network derived by
PGnet is associated to the relapse outcome. Using SVM
machine-learning to improve the predictions in a 3-fold
cross over design, PGnet achieved a AUC = 0.67 (p = 1.6%)
(Figure 3 in this manuscript). Precision and recall of the
predictor in cross-validation studies are also significant
(Suppl. Fig. 4 (Additional file 7)). The evaluation
confirmed the detection of co-expression biomodules
Figure 3
Evaluation of the outcome predictor of "ALL
Relapse" derived from the mechanism-anchored
expression profile obtained by PGnet. The 87 leukemia
patients with "CCR" or "relapse" information were randomly
divided into three folds, two of which were used to identify
the predictor of outcome ("CCR" vs. "relapse", Figure 2c).
The predictor consisted of GEMs and ESGs associated to
"relapse" to train a linear SVM model, and the remaining one
was used as a blinded test set. Three-fold cross-validations
were repeated 100 times. The resulting Receiver Operating
Characteristic (ROC) curve, the area under the curve (AUC)
and corresponding p-values were calculated by Bioconductor
package verification. Horizontal and vertical "error bars"
represent the 95% confidence intervals of the predictor.
Regions where the error bars are above the diagonal line
represent a better prediction than chance. Overall, the AUC
was significantly different than that of a random predictor of
"ALL relapse" (P = 1.6%).
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Details on the expression biomodule associated with BCR-ABL and T-ALL phenotypes and the epigenetic
mechanism of HDAC4. The ESG (gene symbol in red) is positively correlated with part of its GEMs (n = 10) as down-
regulated in "BCR-ABL" and up-regulated in "T-ALL", and negatively correlated with another parts of its GEMs (n = 36).
47 genes were derived from PGnet under optimal threshold (Suppl. Table 3 (Additional file 4)). The standard full
agglomerative hierarchical clustering was performed on Spearman's rank correlation distance of normalized
expression levels. The resulting heatmap was drawn using Bioconductor package made4.
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identification of ALL with poor prognosis [46]. Supple-
mentary Table 5 (Additional file 8) reports 52 robust
GEMs together with 3 robust ESGs (CBX5, SMARCA4
and DNMT3A) associated with leukemia relapse (Suppl.
Methods (Additional file 1)).
We further proceeded to identify biological enrichment
in the distinct sets of genes associated with response to
therapy and long-term maintenance of disease remis-
sion. There were 4 ESGs and a total of 39 GEMs
associated with the phenotype “Relapse”,s u c ha s
C C N A 2 ,B U B 1 ,M A D 2 L 1 ,C D C 4 5 Land CCNB2,e t c ,
which were significantly enriched in one GO term: ATP
binding (hypergeometric p = 3.5 × 10
-6,S u p p l .T a b l e4
(Additional file 9)). Interesting, ATP has been reported
as treatment target of murine leukemic cells in vitro to
reduce the number of leukemic clonogenic cells [47].
Of note, PGnet is designed to discover mechanism-
anchored biomodules that are phenotype-specific and
that are consistently co-expressed across every patient.
Figure 4 shows genes that are down-regulated in one
phenotype and up-regulated in another phenotype and
vice-versa (Suppl. Table 3 (Additional file 4)). In PGnet,
67 genes are involved in the expressional biomodules
that are co-expressed with HDAC4 and DNMT3B, and yet
are differentially expressed between “T-ALL” and “BCR-
ABL” phenotypes. Enrichment analysis of these genes
revealed only one significant enrichment: “MHC class II
receptor activity” (GO:0032395, hypergeometric p-value
=1 . 6×1 0
-11, Suppl. Table 4 (Additional file 9)). Further
identification of the intersected regulation function of
these epigenetic bio-modules requires experiments
in vitro.
The GEMs derived from PGnet can distinguish their
associated phenotype in addition to be co-expressed
with their associated seed gene on transcript level. As an
example in this study, Supplementary Figure 5 (Addi-
tional file 10) shows that the expression of 61 GEMs can
clearly distinguish samples of “Hyperdiploid>50” from
other ALL samples. There were 4 ESGs associated with
the hyperdiploid karyotypes by PGnet. HDAC6 is a class
IIB histon deacetylase and identified as target of anti-
leukemia therapy [48]. Inhibition of HDAC6 disrupts the
association of HSP90 with its chaperon proteins, result-
ing in ubiquitylation of certain oncogenes, such as Bcr-
Abl [49]. Three other genes were also down-regulated
(SMARCA4, BAZ2A and SMARCC2): SMARCA4 is a drug
target candidates in hyperdiploid multiple myeloma
[50]; BAZ2A is a novel nucleolar chromatin remodeling
machine [51], and SMARCC2 was among the top
discriminating genes in the good prognosis subgroup
of MLL [52]. Moreover, GEMs identified by PGnet
significantly enriched among the top-100 marker genes
in previous genome-scale studies of ALL (Fisher’st e s t
p<2×1 0
-16,S u p p l .T a b l e6( A d d i t i o n a lf i l e1 1 ) ) .
Discussion
Comparison of the derived network with other
computational methods
ARACNE [24,53] software was used to reverse engineer
the transcriptional network in two ways. First, by
providing the genes expression data for entire ALL
samples as input, we compared our GEMs with genes
identified by ARACNE (Result is given in Suppl. Table 7
(Additional file 12)). We provided ARACNE our 48
epigenetic seed genes and the expression data for
samples in each phenotype as input, irrespectively.
Subsequently, we got 12 different phenotype specific
gene-gene networks. Each ARACNE network detects
thousands of genes that with significant (p < 0.05)
mutual information (MI) with inputted ESGs. By design,
am a j o r i t yo ft h eg e n e sd e t e c t e db yA R A C N Ea r en o t
phenotype specific. GEMs predicted by PGnet overlap
with ARACNE’s prediction for 31 of 33 ESGs (Suppl.
Table 8 (Additional file 13)). However, PGnet differs
from ARACNE in that it provides phenotypic informa-
tion left out in ARACNE.
ARACNE, FunNet and PGnet provide co-regulation
networks as an output and are thus “related”;h o w e v e r ,
they differ in several important ways: (i) PGnet and
FunNet combine supervised technology and non-para-
metric methodology while ARACNE uses information
theory; (ii) inputs to PGnet are expression levels and
phenotypic associations of interest such as seed genes
whereas FunNet requires full expression together with a
reference list of all transcripts to be analyzed and
ARACNE uses expression data exclusively; (iii) FunNet
abstracts transcriptional functions from co-expression
layer; and consequently (iv) PGnet’s output is a tripartite
network consisting of co-regulated genes and clinical/
genetic characteristics of interest while ARACNE’so r
FunNet’s outputs are uni-partite graphs. (v) The sig-
nificant threshold of PGnet relates to the complete
ordering of all genes to be analyzed whereas the
significant threshold of FunNet is related to the co-
expression of single gene. (vi) PGnet not only provides a
degree of association between phenotypes but also sheds
light on whether there was concordance in the direction-
ality of the changes in expression level.
PGnet parallelizes two input vectors and finds sets of
GEMs via vectorial enrichment optimization. Using
measurements of differential expression and co-expres-
sion together, PGnet is more reliable in discovering
phenotype-specific biomodules that are consistent across
BMC Bioinformatics 2009, 10(Suppl 9):S6 http://www.biomedcentral.com/1471-2105/10/S9/S6
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expressed pattern of the epigenetic seed genes (ESGs)
alone. First, a simplified method identifies none of
GEMs from PGnet. However, we have shown some
evidence indicating that the GEMs are more likely to be
involved in specific epigenetic events than those directly
calculated to be correlated to a phenotype of interest.
Second, simpler alternate methods relying on co-expres-
sion or differential expression separately would identify
only a the subset of ESGs from PGnet (data not shown),
because these methods use an arbitrary threshold for
significance of each gene and neglect the joint analysis of
co-expression patterns with those of differential expres-
sion. In contrast, the “ESG-phenotype” linkage, which
we proposed in PGnet, would be significant even if the
epigenetic seed gene itself is not “significantly” differen-
tially expressed in the linked phenotype (for instance,
the seed genes that are not self-linked in Suppl. Fig. 1
(Additional file 14)).
Biologically, PGnet is an attractive technique as we know
that mechanism-related genes have similar patterns of
expression [4,20], and pathological mechanisms are
easier to understand than genes by clinicians. Addition-
ally, the non-parametric rank-correlation algorithm that
we previously developed for Bioconductor can use the
full range of the expression data for discovery instead of
arbitrary statistical cut-offs [37-39]. We have extended it
to derive phenotype-genotype correlations based on
prior knowledge in addition to gene expression. More-
over, this tri-partite network allows to view genes for
which the expression is specific to a phenotype of
i n t e r e s ta n da l s oa n c h o r e dt oab i o l o g i c a lm e c h a n i s m .
Future studies and limitations
Epigenetic gene regulation is one among many possible
mechanisms involved in disease-specific gene aberrant
activation. Better predictors of outcome can be devel-
oped using a more comprehensive number of biological
mechanisms. The PGnet method could be expanded to a
broader variety of biological mechanisms in order to
provide more accurate mechanism-anchored profiles
that predict therapeutic outcome (e.g. transcriptional
and microRNA networks [54], Gene Ontology terms,
KEGG, etc), however additional methods are required to
control for multiplicity of mechanism while preserving
accuracy of the derived tripartite networks. In addition,
this PGnet is a supervised method that relies on prior
knowledge about seed genes or gene products that
regulate epidemic processes. Therefore, PGnet may
“skew” the network accordingly, which may reflect only
subset of the real regulatory relationship. Further
improvement for finding disease associated and seed-
gene regulated genes will likely require a refined
assessment of co-expression, e.g. mutual information
[24,55], instead of linear Pearson coefficient [37]. By
design, PGnet identifies biomodules that are consistently
co-expressed with the mechanism seed genes across all
patient samples. However, there could exist mechanisms
that are only co-expressed in some specific phenotypes
and otherwise the co-expression patterns are lost. These
particular biomodules may also contribute to mechan-
ism-anchored predictors and require further methodo-
logical developments for their ascertainment. Future
evaluations comparing the PGnet-derived predictors in
other datasets are required, and we intend to proceed
with multi-mechanism profiling that would in theory
achieve higher precision and recall.
Conclusion
We introduced and evaluated a novel algorithm, PGnet,
to identify mechanism-anchored co-expression networks
and to predict therapeutic outcome. PGnet differs from
previous reverse engineering methods in that it provides
a more comprehensive output consisting of a tripartite
network of expression similarity between genes, biolo-
gical mechanisms and clinical phenotypes. Additionally,
statistical significance is conducted over expression
ordering inclusive of the complete array.
Trained on epigenetic mechanisms, PGnet accurately
classified patients in the leukemia subtype and the
relapse group, and these results suggest that a more
comprehensive multi mechanism-based profile may
achieve higher accuracy scores. The proposed method is
scalable, in principle, to other mechanisms such as
transcriptional networks, microRNA-regulated or Gene
Ontology classes. In addition, the produced “similarity
linkages” between mechanisms and genes comprise
magnitude and direction (correlated or anti-correlated),
which could also be utilize to infer regulation (activation
or suppression) [15].
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